Integrated Neuromodulation System for Mood Enhancement of a Living Human Subject

A fluid, non-prescription, blended formulation suitable for oral ingestion by a living human subject, and which after ingestion is able to initiate a more positive mood and to induce an observable enhancement of cognitive functions in a living human subject, said fluid blended formulation comprising:

• a controlled fluid admixture of five essential active ingredients, each of which is able to pass the blood-brain barrier in-vivo, said controlled admixture being limited to
• (i) at least two and not more than six different naturally existing nootropic dopamine neurotransmitter agonists,
• (ii) at least one and not more than four different naturally existing nootropic acetylecholine neurotransmitter agonists,
• (iii) at least one and not more than three different naturally existing nootropic serotonin neurotransmitter agonists,
• (iv) at least one and not more than three different naturally existing nootropic gamma-aminobutyric acid neurotransmitter agonists,
• (v) at least one and not more than three different naturally existing nootropic adenosine antagonists,
• wherein the ratio of all individual nootropic neurotransmitter agonists to all individual nootropic adenosine antagonists is proportionally not less than 5:1 and not more than 16:3, and
• wherein the neurotransmitter replenishment balance for the admixture of essential active agents mathematically is zero (“0”) in value;
• and
• a biocompatible and non-toxic liquid carrier medium suitable for ingestion by a living human subject.

A method for initiating an improvement of human mood and inducing an observable enhancement of cognitive functions in a living human subject, said method comprising the steps of:

• obtaining an orally ingestable non-prescription blended formulation comprising an admixture of essential agents limited to
• (a) not less than two and not more than six different naturally existing nootropic dopamine neurotransmitter agonists which are present in a total quantity ranging from about 200 mg/L to about 36,000 mg/L,
• (b) not less than one and not more than four different naturally existing nootropic acetylecholine neurotransmitter agonists which are present in a total quantity ranging from about 20 mg/L to about 6,000 mg/L,
• (c) at least one and not more than three naturally existing nootropic serotonin neurotransmitter agonists which are present in a total quantity ranging from about 10 mg/L to about 4,800 mg/L,
• (d) at least one and not more than three naturally existing nootropic gamma-aminobutyric acid neurotransmitter agonists which are present in a total quantity ranging from about 10 mg/L to about 15,000 mg/L, and
• (e) at least one and not more than three nootropic adenosine antagonists which are present in a total quantity ranging from about 10 mg/L to about 300 mg/L,
• wherein the ratio of all individual nootropic neurotransmitter agonists to all individual nootropic adenosine antagonists is proportionally not less than 5:1 and not more than 16:3, and
• wherein the minimal weight to volume (mg/L) ratio for all individual neurotransmitter agonists to all individual adenosine antagonists is proportionally not less than about 23:1, and
• wherein the neurotransmitter replenishment balance for the admixture of essential active agents mathematically is zero (“0”) in value;
• orally administering said blended formulation to a living human subject in a predetermined quantity sufficient to initiate an improvement of human mood and induce an observable enhancement of cognitive functions in a living human subject;
• allowing at least a minimal time period after ingestion for said orally administered quantity of blended formulation to become assimilated by and to act within the body of said living human subject;
• periodically monitoring the human subject for objective indications of a positive mental state and an observable enhancement of cognitive functions;
• and
• determining from said objective indications that a more positive mental state exists and an observable enhancement of cognitive functions has occurred in the living human subject.